CN116490182A - 新的吲唑乙炔衍生物 - Google Patents

新的吲唑乙炔衍生物 Download PDF

Info

Publication number
CN116490182A
CN116490182A CN202180079840.XA CN202180079840A CN116490182A CN 116490182 A CN116490182 A CN 116490182A CN 202180079840 A CN202180079840 A CN 202180079840A CN 116490182 A CN116490182 A CN 116490182A
Authority
CN
China
Prior art keywords
methyl
indazol
imidazol
thiazol
piperidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180079840.XA
Other languages
English (en)
Chinese (zh)
Inventor
C·多伦特
A·古尔吉勒尔
D·S·休温斯
G·耶施克
U·奥布斯特·桑德尔
A·里奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN116490182A publication Critical patent/CN116490182A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180079840.XA 2020-12-01 2021-11-29 新的吲唑乙炔衍生物 Pending CN116490182A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20210859 2020-12-01
EP20210859.3 2020-12-01
PCT/EP2021/083279 WO2022117477A1 (en) 2020-12-01 2021-11-29 New indazole acetylene derivatives

Publications (1)

Publication Number Publication Date
CN116490182A true CN116490182A (zh) 2023-07-25

Family

ID=73654642

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180079840.XA Pending CN116490182A (zh) 2020-12-01 2021-11-29 新的吲唑乙炔衍生物

Country Status (15)

Country Link
US (1) US20240002390A1 (https=)
EP (1) EP4255908A1 (https=)
JP (1) JP7840327B2 (https=)
KR (1) KR20230116799A (https=)
CN (1) CN116490182A (https=)
AR (1) AR124170A1 (https=)
AU (1) AU2021393722A1 (https=)
CA (1) CA3197659A1 (https=)
CL (1) CL2023001440A1 (https=)
CO (1) CO2023006912A2 (https=)
CR (1) CR20230218A (https=)
IL (1) IL303064A (https=)
MX (1) MX2023006176A (https=)
PE (1) PE20240099A1 (https=)
WO (1) WO2022117477A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114008049B (zh) 2019-06-21 2024-07-05 豪夫迈·罗氏有限公司 用于癌症治疗的egfr抑制剂
JP7840324B2 (ja) 2020-12-01 2026-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
JP2025516543A (ja) * 2022-05-13 2025-05-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987914C (en) * 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
SG11202011818YA (en) * 2018-06-29 2020-12-30 Hoffmann La Roche Compounds
CN113993591A (zh) * 2019-06-21 2022-01-28 豪夫迈·罗氏有限公司 新egfr抑制剂

Also Published As

Publication number Publication date
US20240002390A1 (en) 2024-01-04
JP7840327B2 (ja) 2026-04-03
PE20240099A1 (es) 2024-01-18
CR20230218A (es) 2023-07-07
CA3197659A1 (en) 2022-06-09
EP4255908A1 (en) 2023-10-11
JP2023550902A (ja) 2023-12-06
WO2022117477A1 (en) 2022-06-09
TW202237611A (zh) 2022-10-01
AR124170A1 (es) 2023-02-22
CL2023001440A1 (es) 2023-12-01
CO2023006912A2 (es) 2023-06-09
MX2023006176A (es) 2023-06-08
AU2021393722A1 (en) 2023-04-13
KR20230116799A (ko) 2023-08-04
IL303064A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
CN113993873B (zh) 用于治疗癌症的egfr抑制剂
JP7840324B2 (ja) 新規インダゾール誘導体
JP7222590B2 (ja) ３－アザビシクロ［３，１，１］ヘプタン誘導体及びこれを含む薬学的組成物
CN116490182A (zh) 新的吲唑乙炔衍生物
US20240408064A1 (en) Ras inhibitors, compositions and methods of use thereof
JP7798887B2 (ja) 新規インダゾール誘導体
CN113993589A (zh) 新egfr抑制剂
CN114746150A (zh) Egfr抑制剂
CN119173518A (zh) 新的吲唑衍生物
RU2853003C1 (ru) Новые индазолацетиленовые производные
WO2023209090A1 (en) Bicyclic heteroaromatic compounds and their application in the treatment of cancer
HK40094041A (zh) 新的吲唑乙炔衍生物
TWI915460B (zh) 新穎吲唑乙炔衍生物、製備其之方法、包含其之醫藥組合物及其用途
HK40115444A (zh) 新的吲唑衍生物
HK40092553A (zh) 新的吲唑衍生物
HK40092556A (zh) 新的吲唑衍生物
HK40071776A (en) Egfr inhibitors
HK40067220A (zh) 新egfr抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40094041

Country of ref document: HK